Comparison of Phoenix and VITEK 2 Extended-Spectrum-β-Lactamase Detection Tests for Analysis of Escherichia coli and Klebsiella Isolates with Well-Characterized β-Lactamases
暂无分享,去创建一个
Kenneth S. Thomson | Ellen S. Moland | E. S. Moland | K. Thomson | N. Cornish | Nancy E. Cornish | Seong G. Hong | Kim Hemrick | Christian Herdt | S. Hong | Kim Hemrick | Christian Herdt
[1] Kenneth S. Thomson,et al. Potential Impact of the VITEK 2 System and the Advanced Expert System on the Clinical Laboratory of a University-Based Hospital , 2001, Journal of Clinical Microbiology.
[2] Maurizio Sanguinetti,et al. Characterization of Clinical Isolates of Enterobacteriaceae from Italy by the BD Phoenix Extended-Spectrum β-Lactamase Detection Method , 2003, Journal of Clinical Microbiology.
[3] Harald Seifert,et al. Detection of Extended-Spectrum Beta-Lactamases among Enterobacteriaceae by Use of Semiautomated Microbiology Systems and Manual Detection Procedures , 2007, Journal of Clinical Microbiology.
[4] John Quale,et al. Emergence of KPC-Possessing Klebsiella pneumoniae in Brooklyn, New York: Epidemiology and Recommendations for Detection , 2005, Antimicrobial Agents and Chemotherapy.
[5] G. Jacoby,et al. More extended-spectrum beta-lactamases , 1991, Antimicrobial Agents and Chemotherapy.
[6] D. Mack,et al. Comparison of BDPhoenix and VITEK2 automated antimicrobial susceptibility test systems for extended-spectrum beta-lactamase detection in Escherichia coli and Klebsiella species clinical isolates. , 2003, Diagnostic microbiology and infectious disease.
[7] P. Nordmann,et al. Acquired carbapenem-hydrolyzing beta-lactamases and their genetic support. , 2002, Current pharmaceutical biotechnology.
[8] D. Landman,et al. Detection of KPC Carbapenem-Hydrolyzing Enzymes in Enterobacter spp. from Brooklyn, New York , 2005, Antimicrobial Agents and Chemotherapy.
[9] Armand Paauw,et al. Evaluation of the Etest ESBL and the BD Phoenix, VITEK 1, and VITEK 2 Automated Instruments for Detection of Extended-Spectrum Beta-Lactamases in Multiresistant Escherichia coli and Klebsiella spp , 2002, Journal of Clinical Microbiology.
[10] Wonkeun Song,et al. Prevalence of Newer β-Lactamases in Gram-Negative Clinical Isolates Collected in the United States from 2001 to 2002 , 2006, Journal of Clinical Microbiology.
[11] Neil Woodford,et al. Outbreak of Klebsiella pneumoniae Producing a New Carbapenem-Hydrolyzing Class A β-Lactamase, KPC-3, in a New York Medical Center , 2004, Antimicrobial Agents and Chemotherapy.
[12] M. Ferraro. Performance standards for antimicrobial susceptibility testing , 2001 .
[13] Maurizio Sanguinetti,et al. Evaluation of the New VITEK 2 Extended-Spectrum Beta-Lactamase (ESBL) Test for Rapid Detection of ESBL Production in Enterobacteriaceae Isolates , 2006, Journal of Clinical Microbiology.
[14] P. Bradford,et al. Emergence of carbapenem-resistant Klebsiella species possessing the class A carbapenem-hydrolyzing KPC-2 and inhibitor-resistant TEM-30 beta-lactamases in New York City. , 2004, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.
[15] R. Goering,et al. Plasmid-mediated, carbapenem-hydrolysing beta-lactamase, KPC-2, in Klebsiella pneumoniae isolates. , 2003, The Journal of antimicrobial chemotherapy.
[16] E. S. Moland,et al. Use of Microdilution Panels with and without β-Lactamase Inhibitors as a Phenotypic Test for β-Lactamase Production among Escherichia coli, Klebsiella spp.,Enterobacter spp., Citrobacter freundii, andSerratia marcescens , 1999, Antimicrobial Agents and Chemotherapy.
[17] K. Thomson. Controversies about extended-spectrum and AmpC beta-lactamases. , 2001, Emerging infectious diseases.